Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03371017 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 595
- Enrollment target
NCT03371017 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 595 participants.
The verdict
NCT03371017, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 595 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Capecitabine
- DRUG Atezolizumab
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 595 participants |
| Start Date | 2018-01-11 |
| Est. Completion | 2024-10-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03371017
The ClinicalTrials.gov registry entry for NCT03371017 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 595 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT03371017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03371017 about?
NCT03371017 is a clinical study titled "A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer". This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).
What is the current status of trial NCT03371017?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 595 participants. The study started on 2018-01-11. Estimated completion is 2024-10-23.
What interventions are being tested in trial NCT03371017?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Capecitabine (DRUG), Atezolizumab (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT03371017?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.